ReviewFrontiers in digital health2026
The EU AI Act: implications and compliance guidance for healthcare facilities.
Review in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The European Union AI Act [Regulation (EU) 2024/1689] establishes the first comprehensive legal framework for artificial intelligence. While AI offers transformative potential in healthcare, its deployment introduces risks regarding safety, bias, and accountability. There is currently a lack of practical operational frameworks to help healthcare facilities transition from legal theory to clinical compliance. Methods: We performed a qualitative regulatory analysis of the EU AI Act, specifically focusing on the obligations of "deployers" (Articles 26, 27, and 50) in clinical settings. The Act's requirements were cross-referenced with established clinical governance standards (e.g., MDR 2017/745 and FUTURE-AI guidelines). A 10-step compliance roadmap was synthesized and exemplified through a hypothetical case study of a high-risk multimodal breast cancer AI system. Results: The analysis identifies healthcare as a primary focus of the Act, with most clinical AI tools classified as "high-risk". We established a four-phase implementation framework: (1) Foundational Strategy and Governance, (2) System Analysis & Risk Assessment, (3) Operational Integration, and (4) Ongoing Compliance. Key results include the definition of mandatory Fundamental Rights Impact Assessments (FRIA), requirements for site-specific technical validation, and the necessity of establishing trust through structured human oversight mechanisms to mitigate automation bias. Conclusion: The EU AI Act necessitates a shift from transactional procurement to a lifecycle-spanning compliance partnership between vendors and hospitals. While the administrative burden is substantial, the Act provides the essential framework for the safe scaling of medical AI. Proactive alignment with these standards, particularly regarding AI literacy and human oversight, is a strategic necessity for healthcare facilities to ensure patient safety and regulatory readiness by the August 2026 enforcement deadline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.